alexa Monitoring of HIV-Infected Children Receiving Highly Active Antiretroviral Therapy in Togo: A Multicentric Study of 854 Children | OMICS International
ISSN 2155-6113
Journal of AIDS & Clinical Research
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Monitoring of HIV-Infected Children Receiving Highly Active Antiretroviral Therapy in Togo: A Multicentric Study of 854 Children

d’Almeida S1, Singo A1, Mouhari-Toure A2, Lawson-Evi K3, Djadou EK4, Saka B2, Messan K5, Agbeko Y6, Azouma D7, Koda K8, Rigaud M9, Ricciardi T9, Adam Z1, Deku K1 and Pitche VP1,2*

1National AIDS Program, Ministry of health, Togo

2Department of Dermatology and STI, Teaching hospital of Tokoin, University of Lome, Togo

3Department of Pediatrics, Teaching hospital of Tokoin, University of Lome, Togo

4Department of Pediatrics, Regional Hospital of Tsevie, Togo

5Espoir-Vie Togo Association, Lome, Togo

6Department of Pediatrics, Regional Hospital of Sokode, Togo

7Department of Pediatrics, Teaching hospital of Kara, University of Kara, Togo

8District hospital of Kouve, Togo

9Clinton Health Access Initiatives, Togo

*Corresponding Author:
Vincent P. Pitche
National AIDS Program, Ministry of Health
BP 81056 Lome, Togo
E-mail: [email protected]

Received Date: December 09, 2011; Accepted Date: March 27, 2012; Published Date: March 29, 2012

Citation: d’Almeida S, Singo A, Mouhari-Toure A, Lawson-Evi K, Djadou EK, et al. (2012) Monitoring of HIV-Infected Children Receiving Highly Active Antiretroviral Therapy in Togo: A Multicentric Study of 854 Children. J AIDS Clinic Res 3:145. doi:10.4172/2155-6113.1000145

Copyright: © 2012 d’Almeida S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of AIDS & Clinical Research


Objective: The purpose of this study was to document the outcome of HIV-infected children receiving the Highly Active Antiretroviral Therapy (HAART) in Togo.

Patients and method: It was a retrospective and descriptive multicentric national survey based on records of HIV-infected children who started receiving the HAART before the 31 st of June 2010. The study was conducted in 14 sites throughout the country.

Results: 854 children (under 15 years old) out of 1257 monitored in Togo were included in the survey. During the study period, 715 (84%) of those children were stable patients, always watched over at selected sites. To be noted also, 56 deaths (6%), 69 follow-up lost (8%) and 14 transfers to other sites (2%). Death and follow-up losses rates were higher in children under one year with respective percentages 11.9% and 18.6%. The rate of death was 13.7% in the cohort of 2007, 10.8% in the cohort of 2008, 6.5% in the cohort of 2009 and finally 5% in the cohort of 2010. The survival rate at 12 months was greater than 90% in all the cohorts.

Conclusion: This study shows a gradual improvement in the survival rate of HIV-infected children receiving the HAAART from 2007 to nowadays. The survival rate of children receiving the HAART at 12 months is not different from that of adults. So, it is important to improve qualitative and quantitative care of HIV-infected children in public health programs in sub-Saharan Africa.


Child; HIV infection; Loss to follow up; Survival; HAART


The best strategies to prevent mortality and morbidity of HIV infection in children are not only the Prevention of Mother-to-Child HIV Transmission (PMTCT) programs expenditure, but also the availability of early diagnosis and antiretroviral therapy in a timely manner [1-4]. In this context, World Health Organization (WHO) in 2010 has published the update of guidelines on antiretroviral therapy criteria in children [5]. These criteria have an emphasis on early antiretroviral therapy in HIV-infected children in order to reduce the morbidity and mortality in this age group. According to the UNAIDS report in 2010, sub-Saharan Africa alone accounts for 92% of pediatric HIV infections and 80% of deaths in HIV-infected children [6]. In 2009, the prevalence of HIV infection in Togo was 3.2% in the general population, and out of the 120,000 people living with HIV (PLWHA), 10% were children [7].

In Togo, the implementation of mother-child pair interventions started since 2004 (the PMTCT, the free of charge availability of antiretroviral drugs and laboratory tests, the multiplication of antiretroviral drugs delivery locations, the fixed dose combinations of pediatric formulations) has improved gradually pediatric care with an increase in the number of children receiving the HAART, which increased from 607 in 2008 to 1357 at the end of 2010 [8]. Data on mortality and morbidity of HIV-infected children in sub-Saharan Africa is relatively less important when compared to data in adults [9-14,15]. In Togo, in order to evaluate the interventions of the National AIDS Program that will help in strategic information for improved planning, it was essential to provide the outcome of pediatric care in PLWHA treatment centers. This study specifically aimed to inform on the rates of mortality, follow-up losses of HIV-infected children receiving the HAART in Togo’s health program.

Patients and Method

It was a retrospective multicentric national survey based on records of HIV-infected children who started receiving the HAART before the 31st of June 2010. The study was conducted in medical management of PLWHA sites throughout the country. A number of 14 sites were selected according to the following criteria: i) the prescription of antiretroviral drugs in the site started more than five years ago; ii) the availability of a pediatric unit in the site (Table 1). All the HIV-infected patients (under 15 years old) at the time of the HAART initiation were included in the study. For each child, a questionnaire was used to collect demographic data (age and gender), clinical data (testing conditions and WHO stage), laboratory data (type of HIV and number of T4 lymphocytes), therapeutic data (antiretroviral therapy) and outcome information (lost to follow-up, death or transfer). It had been considered that a child receiving the HAART was lost to follow-up when he was not seen for more than six months in the care center. During the study, the HAART initiation criteria and the regimens were those of WHO in 2006 [16] (Togo has begun the implementation of WHO 2009 recommendations only in April 2011). Moreover, viral load was not available and early diagnosis by Polymerase Chain Reaction (PCR) in children started only in July 2009. Data were collected from patient’s records using ESOPE software (Operational Evaluation and Monitoring of active files of PLWHA: software developed by the program ESTHER). These data were validated in a sample of 10 sites that were randomly selected. The validation consisted of verifying that all the data extracted through ESOPE software in the sites were identified.

Health regions subdivisions Sites Type of care center Number of children included.
Lom e-Commune Teaching hospital of Tokoin (pediatrics) Public 186 (21.8%)
Regional hospital of Lome commune Public 20 (2.3%)
Bè hospital Public 66 (7.7%)
EVT Lome Associative 101 (11.8%)
AMC Lome Associative 94 (11%)
Maritime Disctrict hospital of Kouve Confessional 120 (14.1%)
Regional hospital of Ts evie Public 31 (3.6%)
Plateaux Regional hospital of Kpalime Public 23 (2.7%)
Regional hospital of Atakpame Public 31 (3.6%)
Centrale Regional hospital of Sokode (AED LIDAW) Public 86 (10.1%)
EVT Sokode Associative 26 (3%)
District hospital of Koloware Confessional 24 (2.8%)
Kara Teaching hospital of Kara Public 26 (3%)
Savanes Association « Vivre dans l’esperance » Confessional 20 (2.3%)
Total 854 (100%)

Table 1: List of sites selected by health regions and sectors.


During the study, from the 1,257 children who started receiving the HAART in June 2010 in Togo, 854 (67.9%) were included in our survey (Table 1). The 854 children were divided into four cohorts according to the year of the HAART initiation. The children put on the HAART from 1998 to 2006 were gathered in the 2007 cohort because of their small number (Table 2). In view of the number of children and duration of follow-up (at least 12 months), we analyzed the survival of only three cohorts (2007, 2008 and 2009). The average age of these children at the HAART initiation was 5±3 years (extremes: 3 months and 14 years). The HAART initiation criteria were observed in 92.7% and the HAART initiation regimens were in accordance with national guidelines in 96.8% of cases. At the time of data collect, 715 (84%) children were always watched over at selected sites. There had been 56 deaths (6%), 69 children were lost to follow-up (8%) and 14 children were transferred (2%) to other sites. By comparing the different cohorts, it was remarked that the death rate was going down in recent cohorts, with 13.7% in the 2007 cohort, 10.8% in the 2008 one, 6.5% in the 2009 cohort, and finally 5 % in the 2010 cohort. The one-year survival rate was 90.8% for the 2007 cohort, 91.8% for the 2008 one and 96.2% for the 2009 cohort. A 2-year survival rate was 89.1% for the 2007 cohort and 90.1% for the 2008 one. And 3-year survival rate was 85.4% for the 2007 cohort.

Sex (N=849) Male 442 (52%)
Female 407 (48%)
Sex-ratio (male/female) 1,1
Age group (N=854) [0-1] 149 (17%)
[1-5] 257 (30%)
[5-10] 352 (41%)
[10-14] 96 (11%)
Average time of monitoring 20 ± 30 month  
Circonstances of screening (N=321) PMTCT 112 (35%)
Clinical suspicion 175 (55%)
Volontary test* 34 (11%)
Type of HIV (N=623) HIV1 621(99.7%)
HIV2 0 (0%)
HIV1+2 2 (0.3%)
WHO clinical stages (N=517) Stage 1 149 (29%)
Stage 2 112 (22%)
Stage 3 184 (36%)
Stage 4 72 (14%)
T4 lymphocytes number (N=624) Average for children 0-5 years 635±528
Average for children over 5 years 312±275
Therapeutic regimens (N=854) D4T 3TC NVP 528(61.8%)
AZT 3TC NVP 251(29.4%)
AZT 3TC EFV 25 (2.9%)
AZT 3TC ABC 2 (0.2%)
ABC DDI LPV/r 21 (2.5%)
ABC 3TC LPV/r 1 (0.1%)
AZT 3TC LPV/r 22 (2.6%)
TDF 3TC LPV/r 4 (0.5%)
Repartition of children in cohorts 2007 cohort 103(12.1%)
2008 cohort 68 (8%)
2009 cohort 219(25.6%)
2010 cohort 293(34.3%)
Unknown HAART initiation date 171 (20%)

Table 2: Characteristics of children included.


This study has led to the description of the outcome of more than two thirds (67.9%) of HIV-infected children under HAART in Togo in 2010. Death and losses to follow-up rates were respectively about 6% and 8%. This death rate is lower than the death rate found in the study of the Working Group IeDEA (9.6 deaths per 100 child-years) in children on HAART in West Africa [15]. Although the death rates declined steadily since 2007, probably because of progress made in pediatric care in Togo, they were probably underestimated, if it must be taken into account the children who were lost to follow-up (because the outcome of those children is unknown). Indeed, according to Braitstein et al. [17] in Kenya, 16% of HIV-infected children who were lost to follow-up had died. The study found that mortality was the second cause of losses to follow-up of children after the concealment of HIV status by parents for fear of discrimination. Similarly in Malawi, McGuire et al. [18] had assessed the outcome of HIV-infected patients who had missed one appointment for medical care for more than one month, and their results show that 50% of children who missed their appointments had died. Other causes of children losses to follow-up are travelling, unaffordable transport cost, family conflicts, traditional treatments, dissatisfaction with health care professionals, apparent improvement in child health [17,18]. The prevention of children losses to followup must be understood at two levels: the primary prevention which is to intensify the fight against discrimination and stigma, multiply and create network between HIV management centers, improve quality services in these centers; the secondary prevention will focus on active and early research of the loss to follow-up patients by telephone calls and or home visits.

A significant reduction in mortality and morbidity is known since the advent of antiretroviral therapy in 1996 in Europe [19]. This reduction is less pronounced in sub-Saharan Africa because of the delay in starting treatment due to the low coverage of PMTCT services and screening services. In this study, mortality was higher in children under one year (11.9%). This is in accordance with previous studies [20], especially in Africa where a multicenter study had found that the risk of death during the first and second year of life among HIVinfected children were respectively of 35.2 % and 52.5% [21]. In this study, the maternal death, the immune level of the mother, and the early HIV infection (before the first 4 weeks of life) were factors significantly associated with early death of children during the first 2 years.

In the study of the Working Group IeDEA, only 2% of children had started HAART before the age of one year, however, factors significantly associated with overall mortality were an advanced clinical stage, a T4 lymphocytes percentage below 15% and the year of initiation of HAART (before 2005) [15]. The early use of antiretroviral drugs has made the deaths of those children rare in Europe [19]. In addition, Peacock-Villada et al. [22] showed in a comparative study that the average rate of deaths among children under HAART was significantly lower in developed countries than in developing countries. In this comparison, the T4 lymphocytes and viral load were also better in developed countries, this is likely due to delayed HAART initiation in low-income countries. For Wamalwa et al. [23] in Kenya, anemia with hemoglobin less than 9 grams/deciliter was independently predictive of mortality in children receiving the HAART.

In this descriptive study, we determined the overall rates of survival in children under HAART irrespective of associative factors including the WHO clinical stage at the HAART initiation, the T4 lymphocytes level, the nutritional status of children, the co-infections and the socioeconomic status of parents. Globally, the survival rates of children on HAART at 12 months is superimposed on that of adults (94%) [8], and shows the access to HAART programs importance in African countries in terms of years of life saved.

Indeed, Edmonds et al. [24] in Democratic Republic of Congo (DRC) found after adjustment for confounding factors that HAART reduces the risk of mortality by 75% in children treated compared to untreated children. These results in DRC are similar to those found in Europe, in United States and in South Africa [25,26], and confirm that the mortality of HIV-infected children can be reduced in low-income countries if the policy of universal access to HAART is accompanied by the fight against malnutrition, proper management of co morbidities, and specially early initiation of HAART. In this study, screening was done mainly in case of clinical signs, children screened in the PMTCT centers accounted for only 35% of cases. This suggests that efforts should be continued in routine screening of pregnant women in PMTCT centers in Togo. Indeed, in 2010, the rate of coverage of PMTCT services was 33% and only 30% of pregnant women expected in the country have been tested and antiretroviral prophylaxis was offered to 52% of those women [8]. As part of the program for the elimination of the mother-to-child HIV transmission in 2015, the Togolese Ministry of Health has recently developed a national strategy for the rapid expansion of the PMTCT services, as well as the early detection of HIV by PCR. In addition, the application of the new guidelines for HAART in pregnant women and children will firstly reduce the rate of motherto- child HIV transmission and also significantly improve the care of HIV-infected children.


This study showed that the survival rate of HIV-infected children on HAART was gradually improving since 2007. But, the antiretroviral drugs initiation is delayed because the diagnostic was done after the onset of clinical signs for most children. The country needs to accelerate the expansion of interventions and the provision of PMTCT services in order to decrease the morbidity and mortality of HIV in Togolese children.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

  • Global experts meet on STD - AIDS and Infectious Diseases
    May 30-31, 2018 Auckland, New Zealand
  • 6th World Congress on Control and Prevention of HIV/AIDS , STDs & STIs
    August 27-29, 2018 Zurich, Switzerland
  • 6th International Conference on HIV/AIDS , STDs and STIs
    October 29-30, 2018 San Francisco, USA

Article Usage

  • Total views: 11656
  • [From(publication date):
    March-2012 - Feb 23, 2018]
  • Breakdown by view type
  • HTML page views : 7865
  • PDF downloads : 3791

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version